Fig. 3: Immunodeficient mice support mCA-KB1P tumor engraftment and enable modeling of MRD following adapted TAC chemotherapy. | npj Breast Cancer

Fig. 3: Immunodeficient mice support mCA-KB1P tumor engraftment and enable modeling of MRD following adapted TAC chemotherapy.

From: Enhanced bioluminescence imaging of tumor cells surviving chemotherapy in a murine model of triple-negative breast cancer

Fig. 3: Immunodeficient mice support mCA-KB1P tumor engraftment and enable modeling of MRD following adapted TAC chemotherapy.The alternative text for this image may have been generated using AI.

A–C Tumor growth curves obtained in A FVB/N, B nude and C NSG mice transplanted with parental KB1P (gray shaded lines) or mCA-KB1P (red shaded lines) organoids. D Statistics of the engraftment rate (%) and time (days) of the transplants. E Median engraftment time (days needed after transplantation to reach treatment size). Statistical analysis was performed by One-way ANOVA. Significant differences are marked with asterisks **** p < 0.0001; *** p < 0.001. “par” and “mCA” mark tumor transplants with KB1P parental and mCA-KB1P organoids, respectively. (F, G) Tumor growth and drug response of F nude and G NSG mice transplanted with mCA-KB1P organoids and treated with the TAC(2x,q5) protocol H Relapse-free survival after therapy start of nude and NSG mice transplanted with mCA-KB1P organoids.

Back to article page